Abstract
No public abstract is available from the verified source records.
Vikram Kumar, Mohammed Alfez Sheikh, Nishu Devi, Bharmjeet Dahiya, Archana Ayyagari, Deepti N. Chaudhari, Jayesh Jagannath Ahire
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Introduction to the human gut microbiota
10.1042/bcj20160510 · 2017
The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic
10.1038/nrgastro.2014.66 · 2014
Probiotics: mechanism of action, health benefits and their application in food industries
10.3389/fmicb.2023.1216674 · 2023
Probiotics-based foods and beverages as future foods and their overall safety and regulatory claims
10.1016/j.fufo.2021.100013 · 2021
Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review
10.3390/ph16111615 · 2023
Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review
10.2147/ceg.s85574 · 2015
Effects of probiotics on gut microbiota: an overview
10.3390/ijms25116022 · 2024
Prebiotics and probiotics for gastrointestinal disorders
10.3390/nu16060778 · 2024
More information needed on probiotic supplement product labels
10.1007/s11606-019-05077-5 · 2019
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives
10.3390/microorganisms12030430 · 2024
Lactic acid bacteria in Asian fermented foods and their beneficial roles in human health
10.1007/s10068-024-01634-9 · 2024
Bile acids as modulators of gut microbiota composition and function
10.1080/19490976.2023.2172671 · 2023
Saccharomyces boulardii CNCM I-745: a non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases
10.1007/s00284-020-02053-9 · 2020
Eukaryotic probiotic Saccharomyces boulardii application in clinical trails: a review
2020
Unresolved referenced work
2023
Genomic and phenotypic comparison of Saccharomyces cerevisiae and Saccharomyces boulardii
2025
Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: a trophic effects review
10.1177/1179552217752679 · 2018
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
10.1177/1756283x11428502 · 2012
Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers
10.3389/fmicb.2019.00336 · 2019
Oral consumption of potential probiotic Saccharomyces boulardii strain Unique 28 in patients with acute diarrhoea: a clinical report
10.3920/bm2011.0055 · 2012
Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study
10.1007/s10096-018-3267-x · 2018
Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome
10.1007/s00384-019-03462-4 · 2020
Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease
10.3920/bm2015.0018 · 2015
In vitro study on the effect of Saccharomyces cerevisiae strains on growth and mycotoxin production by Aspergillus carbonarius and Fusarium graminearum
10.1016/j.ijfoodmicro.2012.11.016 · 2013
Bioprospecting Kluyveromyces marxianus as a robust host for industrial biotechnology
10.3389/fbioe.2022.851768 · 2022
A comparative evaluation of the kefir yeast Kluyveromyces marxianus A4 and sulfasalazine in ulcerative colitis: anti-inflammatory impact and gut microbiota modulation
10.1039/d4fo00427b · 2024
In vitro investigation of Debaryomyces hansenii strains for potential probiotic properties
10.1007/s11274-016-2109-1 · 2016
Sequence assembly of Yarrowia lipolytica strain W29/CLIB89 shows transposable element diversity
10.1371/journal.pone.0162363 · 2016
Saccharomyces boulardii CNCM I-745
2017
Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae
10.1128/aem.02201-06 · 2007
Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast Saccharomyces cerevisiae var. boulardii
10.1101/gr.243147.118 · 2019
Saccharomyces boulardii CNCM I-745 supplementation during and after antibiotic treatment positively influences the bacterial gut microbiota
10.3389/fmed.2023.1087715 · 2023
Clinical efficacy comparison of Saccharomyces boulardii and lactic acid as probiotics in acute pediatric diarrhea
10.29271/jcpsp.2018.03.214 · 2018
Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation
10.1111/j.1365-2249.2009.03878.x · 2009
Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis
10.1152/ajpgi.00217.2011 · 2011
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease
10.1111/j.1572-0241.2006.00465.x · 2006
Effectiveness of Saccharomyces boulardii CNCM I-745 in adult Indian patients with diarrhoea: a real-world, multicentre, retrospective, comparative study
10.1007/s40801-024-00424-3 · 2024
A pilot trial of Saccharomyces boulardii in ulcerative colitis
10.1097/00042737-200306000-00017 · 2003
A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life
10.1097/mcg.0b013e318204593e · 2011
Saccharomyces boulardii CNCM I-745 for prevention of antibiotic-associated diarrhea and Clostridioides difficile in China: systematic review and meta-analysis
2024
Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes
10.1053/j.gastro.2006.10.001 · doi-reference
The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis
10.1007/s10620-008-0357-0 · doi-reference
Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review
10.3390/nu15102275 · doi-reference
Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression
10.1016/j.bbrc.2006.02.080 · doi-reference
Saccharomyces boulardii reduced intestinal inflammation in mice model of 2,4,6-trinitrobencene sulfonic acid induced colitis: based on microarray
10.4166/kjg.2010.55.1.33 · doi-reference
The effect of Saccharomyces boulardii primary prevention on risk of hospital-onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with C. difficile infection
10.1093/cid/ciaa808 · doi-reference
Application of Saccharomyces boulardii in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness
10.4240/wjgs.v17.i2.102342 · doi-reference
Efficacy and safety of Saccharomyces boulardii CNCM I-745 for the treatment of pediatric acute diarrhea in China: a systematic review and meta-analysis
10.3389/fcimb.2025.1587792 · doi-reference
Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: a randomized controlled trial
10.1038/s41598-025-04986-2 · doi-reference
Systematic review with meta-analysis: saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
10.1111/apt.13344 · doi-reference
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
10.3748/wjg.v16.i18.2202 · doi-reference
Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial
10.1093/ofid/ofw011 · doi-reference
Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition
10.3748/wjg.v11.i39.6165 · doi-reference
Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii
10.1203/00006450-198602000-00020 · doi-reference
Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor
10.1371/journal.pone.0018427 · doi-reference
Regulation of intestinal barrier function by microbial metabolites
10.1016/j.jcmgh.2021.02.007 · doi-reference
Saccharomyces boulardii CNCM I-745 supernatant improves markers of gut barrier function and inflammatory response in small intestinal organoids
10.3390/ph18081167 · doi-reference
Unique probiotic properties and bioactive metabolites of Saccharomyces boulardii
10.1007/s12602-022-09953-1 · doi-reference
Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats
10.1136/gut.45.1.89 · doi-reference
Comparative digestive physiology
10.1002/j.2040-4603.2013.tb00501.x · doi-reference
Effectiveness of Saccharomyces boulardii in a rat model of colitis
10.3748/wjg.v18.i44.6452 · doi-reference
Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae
10.1128/aem.64.2.564-568.1998 · doi-reference
Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl- secretion in T84 cells
10.1023/a:1026689628136 · doi-reference
Experimental effects of Saccharomyces boulardii on diarrheal pathogens
10.1016/s1286-4579(02)01592-7 · doi-reference
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
10.1128/iai.67.1.302-307.1999 · doi-reference
Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance
10.1128/aem.00325-24 · doi-reference
Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients
10.1046/j.1365-2036.1999.00666.x · doi-reference
Modification of Salmonella typhimurium motility by the probiotic yeast strain Saccharomyces boulardii
10.1371/journal.pone.0033796 · doi-reference
Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimdeurium mutant DT 104 to the surface of Saccharomyces boulardii
10.1046/j.1439-0507.1999.00449.x · doi-reference
AGA Clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders
10.1053/j.gastro.2020.05.059 · doi-reference
Role of probiotics in the treatment and prevention of common gastrointestinal conditions in children
10.5223/pghn.2024.27.1.1 · doi-reference
A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life
10.1097/mcg.0b013e318204593e · doi-reference
A pilot trial of Saccharomyces boulardii in ulcerative colitis
10.1097/00042737-200306000-00017 · doi-reference
Effectiveness of Saccharomyces boulardii CNCM I-745 in adult Indian patients with diarrhoea: a real-world, multicentre, retrospective, comparative study
10.1007/s40801-024-00424-3 · doi-reference
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease
10.1111/j.1572-0241.2006.00465.x · doi-reference
Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis
10.1152/ajpgi.00217.2011 · doi-reference
Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation
10.1111/j.1365-2249.2009.03878.x · doi-reference
Clinical efficacy comparison of Saccharomyces boulardii and lactic acid as probiotics in acute pediatric diarrhea
10.29271/jcpsp.2018.03.214 · doi-reference
Saccharomyces boulardii CNCM I-745 supplementation during and after antibiotic treatment positively influences the bacterial gut microbiota
10.3389/fmed.2023.1087715 · doi-reference
Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast Saccharomyces cerevisiae var. boulardii
10.1101/gr.243147.118 · doi-reference